Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss

Peng Zhang; Jiekai Ye; Jiale Dai; Ying Wang; Genjun Chen; Jinping Hu; Qimiao Hu; Jun Fei

doi:10.3389/fendo.2022.963237

journal article Open Access Dec 19, 2022

Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss

Peng Zhang

Jiekai Ye Jiale Dai Ying Wang

Genjun Chen Jinping Hu

Qimiao Hu Jun Fei

Frontiers in Endocrinology Vol. 13 · Frontiers Media SA

View at Publisher Save 10.3389/fendo.2022.963237

Abstract

Osteoporosis is a common metabolic bone disease with a rapidly increasing prevalence, characterized by massive bone loss because of excessive osteoclast formation. Gallic acid (GA), a phenolic acid isolated from Cornus officinalis, has anti-inflammatory and anti-oxidant effects, but its effect on osteoclast formation has not been confirmed. In our study, we demonstrated that GA significantly inhibited RANKL‐induced osteoclast formation and function of osteoclast in bone marrow monocytes (BMMs) and RAW264.7 cells in a dose-dependent manner without cytotoxicity. For molecular mechanisms, GA repressed osteoclastogenesis by blocking Akt, ERK, and JNK pathways, and suppressed osteoclastogenesis-related marker expression, including nuclear factor of the activated T-cell cytoplasmic 1 (NFATc1), c‐Fos, and cathepsin K (CTSK). In addition, we further assessed the effect of GA in an ovariectomized mouse model, which indicated that GA has a notable effect on preventing bone loss. In conclusion, GA exerts notable effects in inhibiting osteoclastogenesis and preventing ovariectomy-induced bone loss, suggesting that GA is a potential agent in osteoporosis treatment.

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Compston "Osteoporosis" Lancet (2019) 10.1016/s0140-6736(18)32112-3

[2]

Rachner "Osteoporosis: Now and the future" Lancet (2011) 10.1016/s0140-6736(10)62349-5

[3]

Chen "Osteoblast-osteoclast interactions" Connect Tissue Res (2018) 10.1080/03008207.2017.1290085

[4]

Bisphosphonates for the prevention and treatment of osteoporosis

Spyridoula Maraka, Kurt A Kennel

BMJ 2015 10.1136/bmj.h3783

[5]

Reid "Efficacy, effectiveness and side effects of medications used to prevent fractures" J Intern Med (2015) 10.1111/joim.12339

[6]

Vargas-Franco "Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do" J Cell Physiol (2018) 10.1002/jcp.26465

[7]

Wang "Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis" J Cell Mol Med (2019) 10.1111/jcmm.13942

[8]

Jin "Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis" J Cell Mol Med (2019) 10.1111/jcmm.14713

[9]

Bar-Shavit "The osteoclast: A multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell" J Cell Biochem (2007) 10.1002/jcb.21553

[10]

Osteoclast differentiation and activation

William J. Boyle, W. Scott Simonet, David L. Lacey

Nature 2003 10.1038/nature01658

[11]

Akbar "Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions" Mol Med (2017) 10.2119/molmed.2016.00170

[12]

Park "Current understanding of RANK signaling in osteoclast differentiation and maturation" Mol Cells (2017) 10.14348/molcells.2017.0225

[13]

Yuan "Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways" Bone (2015) 10.1016/j.bone.2015.02.017

[14]

Seo "3-Hydroxyolean-12-en-27-oic acids inhibit RANKL-induced osteoclastogenesis in vitro and inflammation-induced bone loss in vivo" Int J Mol Sci (2020) 10.3390/ijms21155240

[15]

Asagiri "The molecular understanding of osteoclast differentiation" Bone (2007) 10.1016/j.bone.2006.09.023

[16]

Tanaka "Terminalia bellirica (Gaertn.) roxb. extract and Gallic acid attenuate LPS-induced inflammation and oxidative stress via MAPK/NF-κB and Akt/AMPK/Nrf2 pathways" Oxid Med Cell Longev (2018) 10.1155/2018/9364364

[17]

Ahn "Gallic Acid-g-Chitosan modulates inflammatory responses in LPS-stimulated RAW264.7 cells Via NF-κB, AP-1, and MAPK pathways" Inflammation (2016) 10.1007/s10753-015-0258-2

[18]

Wang "Gallic Acid inhibits fibroblast growth and migration in keloids through the AKT/ERK signaling pathway" Acta Biochim Biophys Sin (Shanghai) (2018) 10.1093/abbs/gmy115

[19]

Xia "Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis" BioMed Pharmacother (2020) 10.1016/j.biopha.2020.110170

[20]

Xu "Celastrol attenuates RANKL-induced osteoclastogenesis in vitro and reduces titanium particle-induced osteolysis and ovariectomy-induced bone loss in vivo" Front Pharmacol (2021) 10.3389/fphar.2021.682541

[21]

Ono "Recent advances in osteoclast biology" Histochem Cell Biol (2018) 10.1007/s00418-018-1636-2

[22]

Chen "Medical treatment for osteoporosis: From molecular to clinical opinions" Int J Mol Sci (2019) 10.3390/ijms20092213

[23]

Zhao "Gentiopicroside prevents interleukin-1 beta induced inflammation response in rat articular chondrocyte" J Ethnopharmacol (2015) 10.1016/j.jep.2015.06.031

[24]

Haftek "Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skin" Exp Dermatol (2008) 10.1111/j.1600-0625.2008.00732.x

[25]

Chen "Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation" Pharmacol Res (2020) 10.1016/j.phrs.2020.104944

[26]

Kim "Signaling pathways in osteoclast differentiation" Chonnam Med J (2016) 10.4068/cmj.2016.52.1.12

[27]

Kiviranta "Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K" J Bone Miner Res (2001) 10.1359/jbmr.2001.16.8.1444

[28]

Moon "Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade" J Immunol (2012) 10.4049/jimmunol.1101254

[29]

Chen "18β-glycyrrhetinic acid inhibits osteoclastogenesis In vivo and In vitro by blocking RANKL-mediated RANK-TRAF6 interactions and NF-κB and MAPK signaling pathways" Front Pharmacol (2018) 10.3389/fphar.2018.00647

[30]

Cao "Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis" J Biol Chem (2013) 10.1074/jbc.m113.469973

[31]

Yamashita "Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and src signaling" Regul Pept (2010) 10.1016/j.regpep.2010.03.003

[32]

Wu "Gα13 negatively controls osteoclastogenesis through inhibition of the akt-GSK3β-NFATc1 signalling pathway" Nat Commun (2017) 10.1038/ncomms13700

[33]

Zhao "The novel p38 inhibitor, pamapimod, inhibits osteoclastogenesis and counteracts estrogen-dependent bone loss in mice" J Bone Miner Res (2019) 10.1002/jbmr.3655

[34]

Wang "Cryptotanshinone inhibits RANKL-induced osteoclastogenesis by regulating ERK and NF-κB signaling pathways" J Cell Biochem (2018) 10.1002/jcb.28008

[35]

Chen "Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption" Proc Natl Acad Sci USA (2019) 10.1073/pnas.1900881116

[36]

Pacifici "Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis" J Bone Miner Res (1996) 10.1002/jbmr.5650110802

Cited By

34

Pseudo-cereal based yogurt alternatives with focus on processing and nutra-pharmaceutical applications

Pooja Sanasam, Sonia Morya · 2026

Discover Food

Metrics

34

Citations

36

References

Details

Published: Dec 19, 2022
Vol/Issue: 13
License: View

Authors

Qinghai University

Cite This Article

Peng Zhang, Jiekai Ye, Jiale Dai, et al. (2022). Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.963237

Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss

You May Also Like